Xilio Therapeutics (XLO) Change in Cash (2020 - 2026)

Xilio Therapeutics has disclosed Change in Cash across 7 years of filings, most recently posting $12.8 million for Q1 2026.

• Change in Cash for Q1 2026 came in at $12.8 million, down 62.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.3 million (up 13.24% YoY), and the FY2025 annual result was $82.3 million, up 662.98% from the prior year.
• Change in Cash came in at $12.8 million for Q1 2026 at Xilio Therapeutics, down from $33.8 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $40.0 million in Q2 2024 to a low of -$27.1 million in Q1 2023.
• The 5-year median for Change in Cash is -$15.1 million (2023), against an average of -$2.8 million.
• Across the five-year window, Change in Cash sank 119.08% in 2022 and soared 666.57% in 2025, its largest moves.
• Xilio Therapeutics' Change in Cash stood at -$18.8 million in 2022, then increased by 19.69% to -$15.1 million in 2023, then soared by 60.42% to -$6.0 million in 2024, then jumped by 666.57% to $33.8 million in 2025, then tumbled by 62.08% to $12.8 million in 2026.
• The last three Change in Cash figures came in at $12.8 million (Q1 2026), $33.8 million (Q4 2025), and -$17.8 million (Q3 2025), per Business Quant data.